Several brokerages have updated their recommendations and price targets on shares of Alumis (NASDAQ: ALMS) in the last few weeks:
- 5/19/2026 – Alumis had its “buy” rating reaffirmed by Citigroup Inc..
- 5/19/2026 – Alumis had its price target raised by Chardan Capital from $38.00 to $40.00. They now have a “buy” rating on the stock.
- 5/16/2026 – Alumis was downgraded by Wall Street Zen from “hold” to “sell”.
- 5/15/2026 – Alumis had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $39.00 price target on the stock.
- 5/15/2026 – Alumis had its price target raised by Wells Fargo & Company from $49.00 to $51.00. They now have an “overweight” rating on the stock.
- 5/15/2026 – Alumis had its price target raised by Guggenheim from $32.00 to $34.00. They now have a “buy” rating on the stock.
- 5/15/2026 – Alumis was downgraded by HC Wainwright from “buy” to “neutral”. They now have a $25.00 price target on the stock.
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Recommended Stories
- Five stocks we like better than Alumis
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Receive News & Ratings for Alumis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis Inc and related companies with MarketBeat.com's FREE daily email newsletter.
